US to spend $5B on 10M courses of Pfizer's COVID-19 pill

Listen
Text
  • Small
  • Medium
  • Large

The U.S. will buy 10 million courses of Pfizer's COVID-19 antiviral pill Paxlovid for $5 billion, The Washington Post reported Nov. 16.

Paxlovid reduced the risk of hospitalization or death by 89 percent in a phase 3 trial, according to Pfizer. On Nov. 16, the company applied for emergency use authorization from the FDA for the pill.

Pfizer's application comes about a month after Merck asked the FDA for emergency use authorization of molnupiravir, the COVID-19 antiviral pill it is developing with Ridgeback Biotherapeutics. The U.S. signed a deal with Merck in June to purchase 1.7 million courses of molnupiravir for $1.2 billion if it's authorized by the FDA. 

 

Copyright © 2022 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.

 

Featured Whitepapers

Featured Webinars